Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Jade Biosciences, Inc.

NASDAQ: JBIO · Life Sciences · 4 alerts · CIK 1798749

Share price
$15.34Close, Nov 16
Market cap
$1.06B
Shares outstanding
69.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jade Biosciences, Inc. filings on SEC EDGAR ↗

7:30 AM ET 10-Q
Financial Results ▶ Call

Jade Biosciences Q3 2026 Results: Net Loss of $35.1M, Loss Widens

Jade Biosciences reported a net loss of $131.2 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a June 2026 financing and ATM offerings, ending the period with $475.7 million in cash, cash equivalents, and investments.

Key figure
Net loss $35.1M
7:21 AM ET 8-K
Financial Results

Jade Biosciences Financial Results

Jade Biosciences reported third quarter 2026 financial results, highlighting a cash position of $476 million which is expected to fund operations into Q4 2028. The company is preparing to initiate its Phase 3 EVERGREEN trial for JADE101 in IgA nephropathy ahead of schedule in Q4 2026.

Term
Q3 2026

“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile.”

Tom Frohlich, Chief Executive Officer of Jade

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.